Response to Comments: MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis

This policy (A60190) is a response-to-comments document related to MolDX LCD L39935 and does not itself establish clinical coverage criteria for molecular testing for hereditary transthyretin amyloidosis. For specific indications, limitations, documentation requirements, and frequency limits, refer to the referenced LCD L39935 (notice period begins 2025-07-03; effective 2025-08-17).

"This document is a response to public comments on the MolDX Local Coverage Determination (LCD) L39935 and does not specify clinical coverage criteria for molecular testing for hereditary transthyre..."

Sign up to see full coverage criteria, indications, and limitations.